Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.

Leila ARS, Mousa MHA, Frakolaki E, Vassilaki N, Bartenschlager R, Zoidis G, Abdel-Halim M, Abadi AH.

ACS Omega. 2019 Jul 1;4(7):11440-11454. doi: 10.1021/acsomega.9b01242. eCollection 2019 Jul 31.

2.

Emerging Role of l-Dopa Decarboxylase in Flaviviridae Virus Infections.

Frakolaki E, Kalliampakou KI, Kaimou P, Moraiti M, Kolaitis N, Boleti H, Koskinas J, Vassilacopoulou D, Vassilaki N.

Cells. 2019 Aug 5;8(8). pii: E837. doi: 10.3390/cells8080837.

3.

Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species.

Giannakopoulou E, Pardali V, Frakolaki E, Siozos V, Myrianthopoulos V, Mikros E, Taylor MC, Kelly JM, Vassilaki N, Zoidis G.

Medchemcomm. 2019 May 16;10(6):991-1006. doi: 10.1039/c9md00200f. eCollection 2019 Jun 1.

PMID:
31303998
4.

L-Dopa decarboxylase interaction with the major signaling regulator ΡΙ3Κ in tissues and cells of neural and peripheral origin.

Vassiliou AG, Siaterli MZ, Frakolaki E, Gkogkosi P, Paspaltsis I, Sklaviadis T, Vassilacopoulou D, Vassilaki N.

Biochimie. 2019 May;160:76-87. doi: 10.1016/j.biochi.2019.02.009. Epub 2019 Feb 20.

PMID:
30796964
5.

The Role of Tissue Oxygen Tension in Dengue Virus Replication.

Frakolaki E, Kaimou P, Moraiti M, Kalliampakou KI, Karampetsou K, Dotsika E, Liakos P, Vassilacopoulou D, Mavromara P, Bartenschlager R, Vassilaki N.

Cells. 2018 Dec 1;7(12). pii: E241. doi: 10.3390/cells7120241.

6.

Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation Pathway.

Tsitoura E, Kazazi D, Oz-Arslan D, Sever EA, Khalili S, Vassilaki N, Aslanoglou E, Dérian N, Six A, Sezerman OU, Klatzmann D, Mavromara P.

Hum Gene Ther. 2019 Apr;30(4):429-445. doi: 10.1089/hum.2018.161. Epub 2019 Jan 25.

PMID:
30351174
7.

Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.

Ramsis TM, Abdel Karim SE, Vassilaki N, Frakolaki E, Kamal AAM, Zoidis G, Ahmed NS, Abadi AH.

Arch Pharm (Weinheim). 2018 Jul;351(7):e1800017. doi: 10.1002/ardp.201800017. Epub 2018 May 25.

PMID:
29799645
8.

Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.

Lougiakis N, Frakolaki E, Karmou P, Pouli N, Marakos P, Madan V, Bartenschlager R, Vassilaki N.

Chem Biol Drug Des. 2017 Sep;90(3):352-367. doi: 10.1111/cbdd.12966. Epub 2017 Mar 24.

PMID:
28245093
9.

Virus-host interactions under hypoxia.

Vassilaki N, Frakolaki E.

Microbes Infect. 2017 Mar;19(3):193-203. doi: 10.1016/j.micinf.2016.10.004. Epub 2016 Oct 19. Review.

PMID:
27771294
10.

Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma.

Vallianou I, Dafou D, Vassilaki N, Mavromara P, Hadzopoulou-Cladaras M.

Int J Biochem Cell Biol. 2016 Sep;78:315-326. doi: 10.1016/j.biocel.2016.07.027. Epub 2016 Jul 29.

PMID:
27477312
11.

Expression of the novel hepatitis C virus core+1/ARF protein in the context of JFH1-based replicons.

Kotta-Loizou I, Karakasiliotis I, Vassilaki N, Sakellariou P, Bartenschlager R, Mavromara P.

J Virol. 2015 May;89(9):5164-70. doi: 10.1128/JVI.02351-14. Epub 2015 Feb 18.

12.

Hepatitis C virus core+1/ARF protein decreases hepcidin transcription through an AP1 binding site.

Kotta-Loizou I, Vassilaki N, Pissas G, Kakkanas A, Bakiri L, Bartenschlager R, Mavromara P.

J Gen Virol. 2013 Jul;94(Pt 7):1528-34. doi: 10.1099/vir.0.050328-0. Epub 2013 Apr 11.

PMID:
23580428
13.

Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection.

Budkowska A, Kakkanas A, Nerrienet E, Kalinina O, Maillard P, Horm SV, Dalagiorgou G, Vassilaki N, Georgopoulou U, Martinot M, Sall AA, Mavromara P.

PLoS One. 2011 Jan 6;6(1):e15871. doi: 10.1371/journal.pone.0015871.

14.

Internal translation initiation stimulates expression of the ARF/core+1 open reading frame of HCV genotype 1b.

Boumlic A, Vassilaki N, Dalagiorgou G, Kochlios E, Kakkanas A, Georgopoulou U, Markoulatos P, Orfanoudakis G, Mavromara P.

Virus Res. 2011 Jan;155(1):213-20. doi: 10.1016/j.virusres.2010.10.007. Epub 2010 Oct 17.

PMID:
20959129
15.

Prevalence of intrinsic disorder in the hepatitis C virus ARFP/Core+1/S protein.

Boumlic A, Nominé Y, Charbonnier S, Dalagiorgou G, Vassilaki N, Kieffer B, Travé G, Mavromara P, Orfanoudakis G.

FEBS J. 2010 Feb;277(3):774-89. doi: 10.1111/j.1742-4658.2009.07527.x. Epub 2010 Jan 7.

16.

The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product.

Vassilaki N, Mavromara P.

IUBMB Life. 2009 Jul;61(7):739-52. doi: 10.1002/iub.201. Review.

17.

Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication.

Vassilaki N, Friebe P, Meuleman P, Kallis S, Kaul A, Paranhos-Baccalà G, Leroux-Roels G, Mavromara P, Bartenschlager R.

J Virol. 2008 Dec;82(23):11503-15. doi: 10.1128/JVI.01640-08. Epub 2008 Sep 17.

18.

Expression studies of the HCV-1a core+1 open reading frame in mammalian cells.

Vassilaki N, Boleti H, Mavromara P.

Virus Res. 2008 May;133(2):123-35. doi: 10.1016/j.virusres.2007.10.019. Epub 2008 Feb 19.

PMID:
18243391
19.

Supplemental Content

Loading ...
Support Center